The FDA last week approved Pfizer’s Elrexfio for the treatment of relapsed or refractory multiple myeloma in adult patients that have received at least four prior lines of treatment, “including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.” The drug will face off against Johnson & Johnson’s Tecvayli, another BCMA-directed bispecific antibody. Both drugs are administered as subcutaneous injections, though Elrexfio may edge out Tecvayli on convenience. The J&J therapy requires weekly administration, while Elrexfio is given biweekly. For the treatment of multiple myeloma, Tecvayli currently holds covered or better status for 85% of all insured lives under the medical benefit. About 21% of lives have preferred access to Tecvayli.
SOURCE: MMIT Analytics, as of 8/21/23